Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer

Takashi Sasaki, Hiroyuki Isayama, Yousuke Nakai, Yukiko Ito, Ichiro Yasuda, Nobuo Toda, Hiroshi Yagioka, Saburo Matsubara, Keiji Hanada, Hiroyuki Maguchi, Hideki Kamada, Osamu Hasebe, Tsuyoshi Mukai, Yoshihiro Okabe, Iruru Maetani, Kazuhiko Koike

Takashi Sasaki, Hiroyuki Isayama, Yousuke Nakai, Kazuhiko Koike, Department of Gastroenterology, Graduate School of Medicine, the University of Tokyo, Tokyo 113-8655, Japan
Yukiko Ito, Department of Gastroenterology, Japanese Red Cross Medical Center, Tokyo 150-8935, Japan
Ichiro Yasuda, First Department of Internal Medicine, Gifu University Hospital, Gifu 501-1194, Japan
Nobuo Toda, Department of Gastroenterology, Mitsui Memorial Hospital, Tokyo 101-8643, Japan
Hiroshi Yagioka, Department of Gastroenterology, JR Tokyo General Hospital, Tokyo 151-8528, Japan
Saburo Matsubara, Department of Gastroenterology, Kanto Central Hospital, Tokyo 138-8531, Japan
Keiji Hanada, Center for Gastroendoscopy, Onomichi General Hospital, Hiroshima 722-8508, Japan
Hiroyuki Maguchi, Center for Gastroenterology, Teine-Keijinkai Hospital, Hokkaido 006-8555, Japan
Hideki Kamada, Department of Gastroenterology and Neurology Faculty of Medicine, Kagawa University, Kagawa 761-0793, Japan
Osamu Hasebe, Department of Gastroenterology, Nagano Municipal Hospital, Nagano 381-8551, Japan
Tsuyoshi Mukai, Department of Gastroenterology, Gifu Municipal Hospital, Gifu 500-8513, Japan
Yoshihiro Okabe, Department of Gastroenterology, Osaka Red Cross Hospital, Osaka 543-8555, Japan
Iruru Maetani, Division of Gastroenterology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan

Author contributions: Sasaki T designed the study, analyzed the data, and worked on the manuscript; Isayama H designed the study concept; Nakai Y analyzed the data and worked on the manuscript; Ito Y, Yasuda I, Toda N, Yagioka H, Matsubara S, Hanada K, Maguchi H, Kamada H, Hasebe O, Mukai T, Okabe Y and Maetani I collected the clinical data; and Koike K supervised and overviewed the study.

Correspondence to: Hiroyuki Isayama MD, PhD, Department of Gastroenterology, Graduate School of Medicine, the University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. isayama-2im@h.u-tokyo.ac.jp
Telephone: +81-3-38155411-53056 Fax: +81-3-38140021

Accepted: July 15, 2014
Published online: December 28, 2014

Abstract

AIM: To evaluate the differences in the treatment outcomes between the unresectable and recurrent biliary tract cancer patients who received chemotherapy.

METHODS: Patients who were treated with gemcitabine and S-1 combination therapy in the previous prospective studies were divided into groups of unresectable and recurrent cases. The tumor response, time-to-progression, overall survival, toxicity, and dose intensity were compared between these two groups.

RESULTS: Response rate of the recurrent group was higher than that of the unresectable group (40.0% vs 25.5%; \( P = 0.34 \)). Median time-to-progression of the recurrent and unresectable groups were 8.7 mo (95%CI: 1.2 mo, not reached) and 5.7 mo (95%CI: 4.0-7.0 mo), respectively (\( P = 0.14 \)). Median overall survival of the recurrent and the unresectable groups were 16.1 mo (95%CI: 2.0 mo-not reached) and 9.6 mo (95%CI: 7.1-11.7 mo), respectively (\( P = 0.10 \)). Dose intensities were significantly lower in the recurrent groups (gemcitabine: recurrent group 83.5% vs unresectable group 96.8%; \( P < 0.01 \), S-1: Recurrent group 75.9% vs unresectable group 91.8%; \( P < 0.01 \)). Neutropenia occurred more frequently in recurrent group (recurrent group 95% vs unresectable group 55%; \( P = 0.04 \)).

CONCLUSION: Not only the efficacy but also the toxicity and dose intensity were significantly different between unresectable and recurrent biliary tract cancer.
INTRODUCTION

Gemcitabine and cisplatin (GC) combination therapy is currently the standard care for the treatment of advanced biliary tract cancer (BTC)\[^{[4]}\]. The efficacies of GC combination therapy were also confirmed in a study with Japanese patients\[^{[5-9]}\]. However, this study highlighted the differences of efficacy between the unresectable and recurrent cases. In fact, the median overall survival of unresectable and recurrent cases was 9.4 mo and 16.1 mo, respectively.

Extended surgeries, such as a major hepatectomy or a pancreatoduodenectomy, were usually performed for the treatment of BTC. The patients who received these extended surgeries did not usually tolerate the standard dose of chemotherapy and needed dose modifications\[^{[10]}\]. In adjuvant settings, dose modifications were needed, especially after a major hepatectomy, when the patients were treated with gemcitabine and S-1 (GS) combination therapy\[^{[11-13]}\]. However, the same treatment regimens were often delivered for the recurrent cases. Because there is currently no study that evaluates the differences of dose intensity between unresectable and recurrent cases, it is unknown if patients with recurrent tumors can tolerate the standard dose of chemotherapy.

Therefore, we conducted a pooled analysis using two prospective study data to clarify differences in the treatment outcomes between unresectable and recurrent cases receiving GS combination therapy in patients with advanced BTC. GS combination therapy is one of the promising regimens for advanced BTC, and a phase III study comparing GS with GC combination therapy has started in Japan\[^{[14,15]}\].

MATERIALS AND METHODS

Patients and methods

Data from patients treated with GS combination therapy were collected from two prospective studies: the phase II study of GS combination therapy and the randomized phase II study comparing GS combination therapy vs gemcitabine monotherapy\[^{[16]}\]. The same study group conducted these two prospective studies, and the treatment regimens and assessments were the same between these two studies. The enrolled patients were divided into unresectable and recurrent groups and were used to compare the treatment outcomes.

Treatment regimen and dose modification

Gemcitabine was given intravenously at 1000 mg/m\(^2\) over 30 min on days 1 and 15, repeated every 4 wk. S-1 was administered orally, twice daily from days 1 to 14, followed by a 2-wk rest. Three doses of S-1 were established according to the body surface area (BSA) as follows: BSA < 1.25 m\(^2\), 60 mg/d; 1.25 m\(^2\) ≤ BSA < 1.5 m\(^2\), 80 mg/d; and BSA ≥ 1.5 m\(^2\), 120 mg/d. The dose reduction was based on any adverse effects graded according to the National Cancer Institute Common Terminology Criteria of Adverse Events (CTCAE) version 3.0. In the case of a grade 3/4 hematological toxicity or a grade 2 or higher non-hematological toxicity, the treatment was temporarily suspended. After confirming the resolution to a grade 1 toxicity level or lower, the treatment was restarted at a reduced dose. At first, S-1 was reduced to the following doses: BSA < 1.25 m\(^2\), 60 mg/d; 1.25 m\(^2\) ≤ BSA < 1.5 m\(^2\), 80 mg/d; and BSA ≥ 1.5 m\(^2\), 100 mg/d. If the toxicity occurred despite S-1 reduction, the gemcitabine dose was reduced to 800 mg/m\(^2\). If further toxicity was observed, the dose was reduced again. The S-1 dose was reduced to the following doses: BSA < 1.25 m\(^2\), 40 mg/d; 1.25 m\(^2\) ≤ BSA < 1.5 m\(^2\), 60 mg/d; and BSA ≥ 1.5 m\(^2\), 80 mg/d, and the gemcitabine dose was reduced to 600 mg/m\(^2\). If further dose reduction was needed, the study treatment was put on hold. No dose re-escalation was allowed. The study treatments were continued until the disease progression, unacceptable toxicity, or patients’ refusal.

Response and toxicity assessment

The pretreatment evaluation included a medical history and physical examination, a complete blood count, a serum biochemical test, urinalysis and an echocardiogram. The Eastern Cooperative Oncology Group (ECOG) performance status and laboratory tests that included complete blood counts and serum biochemical tests were checked every two weeks. Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels were measured at the beginning of the study and at day
The median time to progressions were 8.7 mo and 5.7 mo, respectively (log-rank test, \( P = 0.43 \)). In Table 4, the incidences of major adverse events are presented except for neutropenia in all grades (recurrent group vs unresectable group, \( P = 0.10 \)). The dose intensities were significantly lower in the recurrent groups than in the unresectable group of both gemcitabine and S-1 treatments.

### Statistical analysis

The objective response rate was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0\(^{(10)}\). The time-to-progression and overall survival were calculated using the Kaplan-Meier method. Fisher’s exact test was used to compare the patients’ characteristics and tumor responses between the two groups. The Mann-Whitney \( U \) test was used to compare quantitative variables as appropriate. The log-rank tests were used to compare the survival curves (overall survival and time-to-progression) between the unresectable group and the recurrent group. The JMP 9.0 statistical software program (SAS Institute Inc., Cary, NC, United States) was used for all statistical analyses.

### RESULTS

#### Patient characteristics

A total of sixty-five patients were enrolled in this pooled analysis. Fifty-five patients were included in the unresectable group and ten patients were in the recurrent group (Table 1). The baseline characteristics were well balanced between these two groups, with the exception of the baseline sum of longest diameter (BSLD). The median BSLDs of the unresectable and recurrent groups were 9.0 cm (range: 1.0-31.9 cm) and 2.8 cm (range: 1.2-16.0 cm), respectively (\( P = 0.04 \)). In ten patients who were enrolled in the recurrent group, two patients had received a major hepatectomy, and a pancreaticoduodenectomy was performed in three patients. One patient received a hepatopancreatoduodenectomy, and a cholecystectomy was performed in four patients.

#### Treatment outcomes

Table 2 summarizes the results of tumor responses. The response rate of the recurrent group was higher than that of the unresectable group (40.0% vs 25.5%; \( P = 0.34 \)). Two patients in the recurrent group achieved complete responses. The disease control rate was similar between these two groups. The median time-to-progression of the recurrent and unresectable groups was 8.7 mo (95%CI: 1.2 mo-not reached) and 5.7 mo (95%CI: 4.0-7.0 mo), respectively (Figure 1; \( P = 0.14 \)). Moreover, the median overall survival of the recurrent and unresectable groups were 16.1 mo (95%CI: 2.0 mo-not reached) and 9.6 mo (95%CI: 7.1-11.7 mo), respectively (Figure 2; \( P = 0.10 \)).

#### Drug administration and toxicity

The median treatment cycles between the unresectable and the recurrent groups were 4 and 7.5 cycles, respectively (\( P = 0.15 \); Table 3). The dose intensities were significantly lower in the recurrent groups than in the unresectable group of both gemcitabine and S-1 treatments.

The incidences of major adverse events are presented in Table 4. The incidence of each adverse event was not statistically significant between these two groups except for neutropenia in all grades (recurrent group...
90% \text{ vs } 89.4; \textit{P} = 0.04). Grade 3-4 neutropenia was also more frequent in the recurrent group than in the unresectable group (60% \text{ vs } 29%; \textit{P} = 0.08). Leukopenia occurred in all grades more frequently in the recurrent group than in the unresectable group (90% \text{ vs } 60%; \textit{P} = 0.08).

**DISCUSSION**

From this pooled analysis, there were several differences in the treatment outcomes between the unresectable and recurrent groups. The median overall survival, the median time-to-progression, and the response rate were better in the recurrent group when compared with the unresectable group. Furthermore, the dose intensity and toxicities were also different between these two groups.

The BSLD was significantly smaller in the recurrent group than in the unresectable group. BSLD is evaluated as the representative of the tumor volume using RECIST criteria. The patients who received surgery are checked for the recurrence by a specific interval, and thus, the recurrence is usually found as a smaller tumor size. However, BTC are sometimes diagnosed at an advanced stage with a larger tumor volume because some BTC lack the characteristic symptoms. The resection rate of BTC in Japan was reported at more than 70%.[19] Therefore, the tumor volumes of unresectable cases usually become large. We hypothesized that the differences of treatment outcomes were mainly affected by the different tumor sizes between these two groups.[20,21]

Major hepatectomies or pancreatoduodenectomies are surgeries often performed for the treatment of BTC. The metabolism of anti-cancer agents is often influenced by a pancreatoduodenectomy.[10] Moreover, a report of a phase 1 study evaluated the recommended dose of GS combination therapy in the adjuvant setting for advanced BTC.[11] A dose reduction was mainly needed after a major hepatectomy when GS combination therapy was used in the adjuvant setting. Although it has not become clear that dose modification was also needed in the recurrent setting, the dose intensity was lower and the adverse events of leucopenia and neutropenia were more frequent in the recurrent group in our study. Therefore, we will need to discuss whether the same regimen can be used both for the unresectable and recurrent cases in the field of advanced BTC.

In clinical studies of advanced BTC, all patients with cancers from all biliary sites were enrolled despite the difference in clinical condition of each biliary site. The prognosis of patients with gallbladder cancers was considered to be poorer than that of other biliary sites.[22,23] However, it is still difficult to evaluate each biliary site separately because of the low accrual rate of clinical study in this field. Because the dose intensities are not usually different between each biliary site, it is reasonable to use the same regimen and to evaluate the treatment outcomes by subset analysis.

The limitation of this pooled analysis was that only a small number of patients were enrolled. Therefore, some data may not be able to detect the significance statistically. However, this pooled analysis might be the first report to evaluate the differences of the treatment outcomes in detail from the data of a prospective study in the field of advanced BTC.[24] It is very important to use the prospectively collected data to evaluate the toxicities precisely. Another limitation was that this analysis was
based on the data of GS combination therapy. GC combination therapy is now the standard of care for advanced BTC in the world. Although GS combination therapy is thought to be a promising regimen in Japan and a phase III study comparing GS with GC combination therapy has started, the influence of extended surgery might be different when a different chemotherapeutic agent is used for treatment. Therefore, further assessment is needed to confirm differences in treatment outcomes for GC combination therapy.\(^{24}\)

In conclusion, not only the efficacy but also the dose intensity and toxicity were different between unresectable and recurrent BTC. The treatment outcomes (response rate, time-to-progression, and overall survival) were better in recurrent cases and are possibly due to the small tumor volume. The dose intensity was significantly lower in recurrent cases, possibly due to the extended surgery. Although the enrollment of patients with advanced BTC for clinical study is still difficult, it may be better to enroll those with unresectable and recurrent BTC separately in future studies.

**REFERENCES**

1. Valle J, Wasan H, Palmer DH, Cunningham D, Anthonype A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281 [PMID: 20375404 DOI: 10.1056/NEJMoa0908721]

2. Sasaki T, Isayama H, Nakay K, Koike K. Current status of chemotherapy for the treatment of advanced biliary tract cancer. Korean J Intern Med 2013; 28: 515-524 [PMID: 24009445 DOI: 10.3904/kjim.2013.28.5.515]

3. Furuse J, Kasuga A, Takasu A, Kitamura H, Nagashima F. Role of chemotherapy in treatments for biliary tract cancer. J Hepatobiliary Pancreat Sci 2012; 19: 337-341 [PMID: 22456744 DOI: 10.1007/s00534-011-0494-2]

4. Tada M, Nakay K, Sasaki T, Hamada T, Nagano R, Mohri D, Miyabayashi K, Yamamoto K, Kogure H, Kawakubo K, Ito Y, Yamamoto N, Sasahira N, Hirano K, Tashiki K, Isayama H, Omata M, Koike K. Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. World J Clin Oncol 2011; 2: 158-163 [PMID: 21611090 DOI: 10.5306/wjco.v2.i3.158]

5. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoa S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103: 469-474 [PMID: 20628385 DOI: 10.1038/bjc.6605779]

6. Valle JW, Furuse J, Jitlal M, Beare S, Mizin N, Wasan H, Bridgewater J, Okusaka T. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 2014; 25: 391-398 [PMID: 24351397 DOI: 10.1093/annonc/mdt540]

7. Furuse J, Okusaka T, Bridgewater J, Taketsuna M, Wasan H, Koshiji M, Valle J. Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. Crit Rev Oncol Hematol 2011; 80: 31-39 [PMID: 21094052 DOI: 10.1016/j.critrevonc.2010.10.009]

8. Sasaki T, Isayama H, Nakay K, Mizuno N, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O, Matsubara S, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M, Koike K. Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Invest New Drugs 2011; 29: 1488-1493 [PMID: 20607585 DOI: 10.1007/s10637-010-9485-4]

9. Sasaki T, Isayama H, Nakay K, Takahara N, Akiyama D, Yagioka H, Kogure H, Matsubara S, Ito Y, Yamamoto N, Sasahira N, Hirano K, Tada N, Tada M, Koike K. A retrospective study of gemcitabine and cisplatin combination therapy as second-line treatment for advanced biliary tract cancer. Chemotherapy 2013; 59: 106-111 [PMID: 24029777 DOI: 10.1159/000354209]

10. Muneoka K, Shirai Y, Sasaki M, Wakai T, Sakata J, Kanda J, Wakabayashi H, Hatakeyama K. [Effect of pylorus-preserving pancreaticoduodenectomy on serum levels of 5-fluorouracil during S-1 treatment for pancreaticobiliary malignancy]. Gan To Kagaku Ryoho 2010; 37: 1503-1506 [PMID: 20716875]

11. Takahara T, Nitta H, Hasegawa Y, Ito N, Takahashi M, Nishizuka S, Wakabayashi G. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures. Cancer Chemother Pharmacol 2012; 69: 1127-1133 [PMID: 22207029 DOI: 10.1007/s00280-011-1805-7]

12. Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Sakabe B, Kobayashi H, Kondo N, Nakagawa N, Sueda T. Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors. J Hepatobiliary Pancreat Sci 2012; 19: 306-313 [PMID: 22270151 DOI: 10.1007/s00534-011-0498-y]

13. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, Nakashima A, Sueda T. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma.
Sasaki T et al. Treatment outcomes of advanced biliary cancer

Ann Surg 2009; 250: 950-956 [PMID: 19953713]

14 Sasaki T, Isayama H, Nakai Y, Ito Y, Kogure H, Ogawa O, Toda N, Yasuda I, Hasebe O, Maetani I, Sasahira N, Hirano K, Tsujino T, Tada M,Omata M. Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2010; 65: 1101-1107 [PMID: 19707761 DOI: 10.1007/s00280-009-1115-5]

15 Kanai M, Yoshimura K, Tsumura T, Asada M, Suzuki C, Niimi M, Matsumoto S, Nishimura T, Nitta T, Yasuchika K, Taura K, Morii Y, Hamada A, Inoue N, Tada S, Yanagihara K, Yazumi S, Osaki Y, Chiba T, Iki I, Fukushima M, Uemoto S, Hatano E. A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2011; 67: 1429-1434 [PMID: 20811895 DOI: 10.1007/s00280-010-1443-5]

16 Sasaki T, Isayama H, Nakai Y, Ito Y, Yasuda I, Toda N, Kogure H, Hanada K, Maguchi H, Sasahira N, Kamada H, Mukai T, Okabe Y, Hasebe O, Maetani I, Koike K. A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer. Cancer Chemother Pharmacol 2013; 71: 973-979 [PMID: 23355041 DOI: 10.1007/s00280-013-2090-4]

17 Morizane C, Okusaka T, Mizusawa J, Takashima A, Ueno M, Ikeda M, Hamamoto Y, Ishii H, Boku N, Furuse J. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial [JCOG 0805]. Cancer Sci 2013; 104: 1211-1216 [PMID: 23763511 DOI: 10.1111/cas.12218]

18 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216 [PMID: 10655437]

19 Miyakawa S, Ishihara S, Horiguchi A, Takada T, Miyazaki M, Nagakawa T. Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 2009; 16: 1-7 [PMID: 19110652 DOI: 10.1007/s00534-008-0015-0]

20 Sasaki T, Isayama H, Nakai Y, Ogawa O, Kogure H, Ito Y, Yamamoto K, Mizuno S, Yagioka H, Yoshimura K, Kawakubo K, Arizumi T, Matsubara S, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K. Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. Cancer Chemother Pharmacol 2011; 67: 845-853 [PMID: 20563811 DOI: 10.1007/s00280-010-1360-7]

21 Machida N, Yoshino T, Boku N, Hironaka S, Onozawa Y, Fukutomi A, Yamazaki K, Yasui H, Taku K, Asaka M. Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer. Jpn J Clin Oncol 2008; 38: 689-694 [PMID: 18945522 DOI: 10.1093/jjco/hyn086]

22 Sasaki T, Isayama H, Nakai Y, Takahara N, Sasahira N, Kogure H, Mizuno S, Yagioka H, Ito Y, Yamamoto N, Hirano K, Toda N, Tada M, Omata M, Koike K. Improvement of prognosis for unresectable biliary tract cancer. World J Gastroenterol 2013; 19: 72-77 [PMID: 23526165 DOI: 10.3748/wjg.v19.i1.72]

23 Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa S, Boku N, Tanaka K, Nagase M, Saisho H, Sato T. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 2007; 37: 843-851 [PMID: 17942578 DOI: 10.1093/jjco/hym116]

24 Ikezawa K, Kanai M, Ajiki T, Tsukamoto T, Toyokawa H, Terajima H, Furuyama H, Nagano H, Ikai I, Kuroda N, Awan M, Ochiai T, Takemura S, Miyamoto A, Kume M, Ogawa M, Takeda Y, Taira K, Ioka T. Patients with recurrent biliary tract cancer have a better prognosis than those with unresectable disease: retrospective analysis of a multi-institutional experience with patients of advanced biliary tract cancer who received palliative chemotherapy. J Hepatobiliary Pancreat Sci 2014; 21: 98-104 [PMID: 23798367 DOI: 10.1002/jhp.2]

25 Toyoda M, Ajiki T, Fujiwara Y, Nagano H, Kobayashi S, Sakai D, Hatano E, Kanai M, Nakamori S, Miyamoto A, Tsui A, Kihara S, Ikoma H, Takemura S, Toyokawa H, Terajima H, Morita S, Ioka T. Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004). Cancer Chemother Pharmacol 2014; 73: 1295-1301 [PMID: 24614947 DOI: 10.1007/s00280-014-2431-y]

P- Reviewer: Tiberio GAM, Zhong JH S- Editor: Qi Y L- Editor: A E- Editor: Wang CH
